

Gambia

Support for Vaccine: Rotavirus This Decision Letter sets out the Programme Terms of a Programme.

| | | | | | | | |
|--|---|---------------------|---------|------|------|------|----------------------|
| 1. Country: | Gambia | | | | | | |
| 2. Vaccine grant number: | 13-GMB-08b-Y, 1316-GMB-13a-X, 17-GMB-13b-X, 1821-GMB-13b-X | | | | | | |
| 3. Date of Decision Letter: | 9/30/2019 | | | | | | |
| 4. Date of the Partnership Framework Agreement: | Sunday, February 3, 2013 | | | | | | |
| 5. Programme title: | New Vaccine Support (NVS), Rotavirus, Routine | | | | | | |
| 6. Vaccine type: | Rotavirus | | | | | | |
| 7. Requested product presentation and formulation of vaccine: | RV1, 1 dose/plastic tube, liq | | | | | | |
| 8. Programme Duration:¹ | 2013-2021 | | | | | | |
| 9. Programme Budget (indicative):² | (subject to the terms of the Partnership Framework Agreement, if applicable) | | | | | | |
| | 2013-2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Total ² |
| Programme Budget (US\$) | 3,703,732 | 253,500 | 345,000 | - | - | - | 4,302,232 |
| 10. Vaccine introduction grant | | | | | | | |
| | Approval | | | | | | |
| | Year | Grant Number | | | | | Amount (US\$) |
| | 2013 | 13-GMB-08b-Y | | | | | 100,000 |
| 11. Product switch grant | Not applicable | | | | | | |
| 12. Indicative Annual Amounts:³ | (subject to the terms of the Partnership Framework Agreement, if applicable) | | | | | | |
| Type of supplies to be purchased with Gavi funds | 2013-2019 | 2020 | | | | | 2021 |
| Number of vaccine doses | | 107,700 | | | | | - |
| Annual Amounts (US\$) | 3,703,732 | 253,500 | | | | | - |
| 13. Procurement agency: | UNICEF. The Country shall release its co-financing payments each year to UNICEF | | | | | | |

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

UNITED .

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2020 | 2021 | 2022 | 2023 | 2024 |
|--|--------|--------|------|------|------|
| Number of vaccine doses | 10,500 | 15,000 | - | - | - |
| Number of AD syringes | - | - | - | - | - |
| Number of re-constitution syringes | - | - | - | - | - |
| Number of safety boxes | - | - | - | - | - |
| Value of vaccine doses (US\$) | 23,075 | 31,383 | - | - | - |
| Total co-financing payments (US\$) (including freight) | 24,000 | 32,500 | - | - | - |

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

| | Due dates |
|--|------------------------------------|
| To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. | 31 March 2020 15 May 2020 |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. | To be agreed with Gavi Secretariat |

| | |
|---|--|
| 18. Financial clarifications: | Country shall provide the following clarifications to Gavi*: |
| Not applicable | |
| * Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements. | |
| 19. Other conditions: | |
| Not applicable | |

Signed by,
On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30/09/2019